Trial Profile
A Phase 3, Randomized, Parallel-Group, Multicenter, Open-Label, Pharmacokinetic, Noninferiority Study of Ravulizumab Administered Subcutaneously Versus Intravenously in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria Currently Treated With Eculizumab
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Jan 2024
Price :
$35
*
At a glance
- Drugs Ravulizumab (Primary) ; Ravulizumab
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Pharmacokinetics; Registrational
- Sponsors Alexion AstraZeneca Rare Disease
- 12 Dec 2023 Results assessing the pharmacokinetics, pharmacodynamics (PD), efficacy, and safety of Subcutaneous ravulizumab through 2 years (day 743) of treatment in adult patients with Paroxysmal Nocturnal Hemoglobinuria previously treated with IV eculizumab, were presented at the 65th American Society of Hematology Annual Meeting and Exposition.
- 16 Oct 2023 Status changed to completed.
- 05 Oct 2023 This trial has been completed in Sweden, according to the European Clinical Trials Database record.